Vivo Capital

Selected news for Vivo Capital, representing 4% of data collected since 11/2017. Recent stories appear in The Markets Daily and Daily Political. This capital firm shares healthcare news with Preventice, Preventice Solutions, Biotech, OrbiMed and dozens of others.

Please provide a valid email address.
Shares Healthcare News With (link):
Healthcare Topics
Companies

Selected Headines

Date Headline (link) Source Relevant Snippet
12/23/2020 Here are the top 5 Houston startup venture capital deals in 2020 innovationmap.com ... to grow its medical device business. Photo via Getty ImagesHouston-based Preventice Solutions, a medical device company, raised a $137 million series B in July . The round was led by Palo Alto-based Vivo Capital along with support from existing investors, including Merck Global Health Innovation Fund, Boston Scientific, and the Samsung Catalyst Fund.The funds were raised in order "to accelerate investment in salesforce expansion, technology and product ...
12/23/2020 Texas expert: Coworking in Houston isn’t going away — it's evolving innovationmap.com ... to grow its medical device business. Photo via Getty ImagesHouston-based Preventice Solutions, a medical device company, raised a $137 million series B in July . The round was led by Palo Alto-based Vivo Capital along with support from existing investors, including Merck Global Health Innovation Fund, Boston Scientific, and the Samsung Catalyst Fund.The funds were raised in order "to accelerate investment in salesforce expansion, technology and product ...
12/22/2020 Ambyint's $15M series B - InnovationMap innovationmap.com ... to grow its medical device business. Photo via Getty ImagesHouston-based Preventice Solutions, a medical device company, raised a $137 million series B in July . The round was led by Palo Alto-based Vivo Capital along with support from existing investors, including Merck Global Health Innovation Fund, Boston Scientific, and the Samsung Catalyst Fund.The funds were raised in order "to accelerate investment in salesforce expansion, technology and product ...
12/17/2020 dMed Completed a US$100 Million Series C Financing stocksnewsfeed.com ... new investors in dMed include Sequoia Capital China, Kaiser Foundation Hospitals and E Fund. They now join the leaders in dMed’s angel, A and B rounds, Qiming Venture Partners, Lilly Asia Ventures, and Vivo Capital , which have taken most of the opportunities to increase their contributions to dMed’s capital since the company’s inception in 2016.dMed Founder, Chairman and CEO, Dr. Lingshi Tan, said “We are extremely ...
11/18/2020 Elevation Oncology Announces $65M Series B Financing and Promotion of Founder Shawn M. Leland to Chief Executive Officer salesandmarketingnetwork.com ... Founder Shawn M. Leland to Chief Executive Officer $65M Series B Raise Led by New Investors venBio Partners and Cormorant Asset Management, with Participation by Boxer Capital of Tavistock Group, Janus Henderson, Samsara Biocapital, Vivo Capital , and All Existing Series A InvestorsShawn M. Leland, Founder of Elevation Oncology, Named Chief Executive Officer; Steve Elms, Managing Partner of Aisling Capital, to Remain Chair of Elevation Oncology Board of Directors NEW YORK ...
11/18/2020 Elevation Oncology Announces $65M Series B Financing and Promotion of Founder Shawn M. Leland to Chief Executive Officer vcaonline.com ... Founder Shawn M. Leland to Chief Executive Officer - $65M Series B Raise Led by New Investors venBio Partners and Cormorant Asset Management, with Participation by Boxer Capital of Tavistock Group, Janus Henderson, Samsara Biocapital, Vivo Capital , and All Existing Series A Investors - - Shawn M. Leland, Founder of Elevation Oncology, Named Chief Executive Officer; Steve Elms, Managing Partner of Aisling Capital, to Remain Chair of Elevation Oncology Board of Directors - NEW ...
10/29/2020 Global clinical-stage cell therapy developer, ‚ÄúGenxi Bio‚Äù received a C round of 100 million US dollars financing electrodealpro.com ... Äù recently announced the completion of a $100 million Series C financing. This round of financing was led by Wellington Management Company, OrbiMed and Morningside Ventures. New investors participating in this round also include Vivo Capital . Existing investors Temasek Holdings, Lilly Asia Ventures, OrbiMed and King Star Med LP also participated.Compared with competing products in the industry, Genxi Bio is characterized by focusing on the development of CAR-T ...
10/28/2020 Gracell Biotechnologies Raises $100 Million in Series C Funding to Advance Next Generation CAR-T Cell Therapies PR Newswire ... therapies for the treatment of cancer, today announced it has secured $100 million in Series C funding. The round is led by Wellington Management Company, OrbiMed and Morningside Ventures, and joined by new investor Vivo Capital . Existing investors Temasek Holdings, Lilly Asia Ventures, OrbiMed and King Star Med LP are also participating."We are very pleased to expand our investor base with support from a high caliber consortium," said Dr ...
10/28/2020 Gracell Biotechnologies Raises $100 Million in Series C Funding to Advance Next Generation CAR-T Cell Therapies intellasia.net ... therapies for the treatment of cancer, today announced it has secured $100 million in Series C funding. The round is led by Wellington Management Company, OrbiMed and Morningside Ventures, and joined by new investor Vivo Capital . Existing investors Temasek Holdings, Lilly Asia Ventures, OrbiMed and King Star Med LP are also participating."We are very pleased to expand our investor base with support from a high caliber consortium," said Dr ...
10/28/2020 Citrine Medicine Advances Efforts to Create the Very First Rare Disease Ecosystem in China Through Strategic Partnership with Bioprojet to License Exclusive Rights for the Use of Orphan Narcolepsy Therapy Wakix(R) (pitolisant) salesandmarketingnetwork.com ... Rare Disease Ecosystem in China Through Strategic Partnership with Bioprojet to License Exclusive Rights for the Use of Orphan Narcolepsy Therapy Wakix(R) (pitolisant) Citrine was founded by Eight Roads, F-Prime Capital, and Vivo Capital ; and closed an $80 Million Series A financing earlier this yearCompany is focused on bringing important rare disease therapies to China while accelerating the rare disease drug development process worldwideWakix® will address high ...
10/23/2020 Vivo Capital Fund Ix, L.P. Buys 250,000 Tarsus Pharmaceuticals, Inc. TARS) Daily Political Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) major shareholder Vivo Capital Fund Ix, L.P. bought 250,000 shares of the company’s on Tuesday, October 20th. The shares were bought at an average price of $16.00 per share, for a total transaction of $4,000,000.00. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.Shares of TARS stock opened at $23.22 on Friday ...
10/23/2020 Insider Buying: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Major Shareholder Buys 250,000 Shares of Stock Ticker Report Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) major shareholder Vivo Capital Fund Ix, L.P. bought 250,000 shares of Tarsus Pharmaceuticals stock in a transaction dated Tuesday, October 20th. The stock was acquired at an average price of $16.00 per share, for a total transaction of $4,000,000.00. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.Shares of NASDAQ:TARS ...
10/22/2020 Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Major Shareholder Acquires $4,000,000.00 in Stock American Banking News Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) major shareholder Vivo Capital Fund Ix, L.P. acquired 250,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 20th. The stock was purchased at an average cost of $16.00 per share, with a total value of $4,000,000.00. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.Tarsus Pharmaceuticals ...
10/22/2020 Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Major Shareholder Acquires $4,000,000.00 in Stock theolympiareport.com Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) major shareholder Vivo Capital Fund Ix, L.P. acquired 250,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 20th. The stock was purchased at an average cost of $16.00 per share, with a total value of $4,000,000.00. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.Tarsus Pharmaceuticals ...
10/17/2020 IPO Launch- Aligos Therapeutics Readies $150 Million U.S. IPO TheStreet ... studies.’ Below is the current status of the company’s drug development pipeline: Source: Company S-1 Filing Investors in the firm have invested at least $182 million and include Roche, Versant Ventures, Baker Bros., Vivo Capital , Novo Holdings and Wellington Management. According to a 2018 market research report by Grand View Research, the global market for Hepatitis B treatments was an estimated $19.6 billion in 2016. The market is forecast ...